|
KMID : 1137020140250020130
|
|
Journal of Gynecologic Oncology
2014 Volume.25 No. 2 p.130 ~ p.135
|
|
|
Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer
|
|
Hahn Ho-Suap
Lee Ki-Heon
Lee In-Ho
Lee Jae-Ho
Whang Chang-Sung
Jo Yeong-Woo
Kim Tae-Jin
|
|
|
Abstract
|
|
|
Objective: The purpose of this study was to compare the in vivo anti-tumor efficacy of a mucoadhesive, lipid-based, oral paclitaxel formulation (DHP107) with traditional, intraperitoneal (IP) paclitaxel using an orthotopic mouse model of chemotherapy-sensitive SKOV3ip1 ovarian cancer.
Methods: To determine the optimal therapeutic dose of oral paclitaxel, DHP107 was administered per os to female athymic nude mice at 0, 25, or 50 mg/kg twice per week. Control mice received 100 μL saline once per week. IP injections of paclitaxel at 5 mg/kg once per week were used for comparison. To evaluate the potential therapeutic effect of metronomic DHP107 chemotherapy, mice received DHP107 50 mg/kg once per week per os, which was compared with 25 mg/kg twice per week and with vehicle-treated controls.
Results: Low-dose DHP107 (25 mg/kg) twice per week was as effective as IP paclitaxel (5 mg/kg once a week) but high-dose DHP107 (50 mg/kg once per week) was less effective at inhibiting tumor growth in an orthotopic mouse model (88%, 82%, and 36% decrease in tumor weight, respectively). Mice that received 25 mg/kg DHP107 twice per week or 50 mg/kg DHP107 once per week per os had a significant decrease in tumor weight compared with vehicle-treated controls (p<0.01, both doses).
Conclusion: Metronomic oral chemotherapy with DHP107 showed anti-tumor efficacy in vivo similar to IP paclitaxel in an orthotopic mouse model.
|
|
|
KEYWORD
|
|
|
Chemotherapy, DHP107, Oral paclitaxel, Ovarian cancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|
|